Print
17 March 2017
GMP News
The Ministry of Industry and Trade of Russia will make changes to the List of bio-targets for developing the analogs of innovative medicinal products that are similar and improved in terms of their pharmacotherapeutic effect.
The need to amend the document is associated with the increased opportunities for the Russian organizations developing narcotic and immunobiological medicinal products to receive subsidies from the federal budget. At this point, the list of bio-targets includes 96 items.
The draft regulatory legal act is expected to come into force in April 2017.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.